Is Frequent Lab Monitoring Necessary?

Dr. Bella Mehta discusses abstract 2619, Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients, presented at the 2024 ACR Convergence meeting in Washington, DC.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×